MA41689A - Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine - Google Patents

Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine

Info

Publication number
MA41689A
MA41689A MA041689A MA41689A MA41689A MA 41689 A MA41689 A MA 41689A MA 041689 A MA041689 A MA 041689A MA 41689 A MA41689 A MA 41689A MA 41689 A MA41689 A MA 41689A
Authority
MA
Morocco
Prior art keywords
prevention
treatment
sleep disorders
dexmedetomidine formulation
dexmedetomidine
Prior art date
Application number
MA041689A
Other languages
English (en)
French (fr)
Inventor
Krishnan Nandabalan
Harsh Negi
Deepa Saini
Sameer Sharma
Frank Yocca
Original Assignee
Bioxcel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Corp filed Critical Bioxcel Corp
Publication of MA41689A publication Critical patent/MA41689A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA041689A 2014-10-15 2015-10-14 Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine MA41689A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462064205P 2014-10-15 2014-10-15

Publications (1)

Publication Number Publication Date
MA41689A true MA41689A (fr) 2017-08-22

Family

ID=55747372

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041689A MA41689A (fr) 2014-10-15 2015-10-14 Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine

Country Status (5)

Country Link
US (3) US20170239221A1 (https=)
EP (1) EP3206685B1 (https=)
JP (4) JP2017534613A (https=)
MA (1) MA41689A (https=)
WO (1) WO2016061413A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102793584B1 (ko) * 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
JP2024511394A (ja) 2021-03-19 2024-03-13 オリオン コーポレーション タシピミジン製剤およびその使用
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
EP4364729A4 (en) * 2021-08-23 2024-11-27 Yichang Humanwell Pharmaceutical Co., Ltd. TRANSDERMAL COMPOSITION OF DEXMEDETOMIDINE, TRANSDERMAL PATCH AND METHOD OF PREPARATION AND USE THEREOF
IL318007A (en) 2022-07-27 2025-02-01 Universit?T Z?Rich Dexmedetocidin for the treatment of sleep disorders
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
KR102853305B1 (ko) * 2023-05-25 2025-09-01 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물
CN117771220B (zh) * 2024-02-28 2024-05-28 山东第二医科大学 一种右美托咪定中药多糖口溶膜剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20090076156A1 (en) * 2005-07-18 2009-03-19 Masud Husain Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
PT1986642E (pt) * 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CN101801346A (zh) * 2007-05-10 2010-08-11 诺瓦德尔药品公司 抗失眠症组合物及方法
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
AU2011204315A1 (en) * 2010-01-08 2012-08-02 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
AU2012352528B9 (en) * 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
CA2924233C (en) * 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Also Published As

Publication number Publication date
US20170239221A1 (en) 2017-08-24
JP2025092508A (ja) 2025-06-19
EP3206685A1 (en) 2017-08-23
US20250099430A1 (en) 2025-03-27
EP3206685B1 (en) 2024-05-08
JP2023076465A (ja) 2023-06-01
US20230414572A1 (en) 2023-12-28
JP2017534613A (ja) 2017-11-24
EP3206685A4 (en) 2018-06-20
WO2016061413A1 (en) 2016-04-21
JP2021080276A (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
MA41689A (fr) Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
IL256166B (en) Compounds for use in treating neuromuscular disorders
MA45192A (fr) Traitement d'association
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
IL247452A0 (en) Compounds for treatment of complement mediated disorders
EP2875826A4 (en) COMPOSITION FOR PREVENTING OR TREATING SEPSIS
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
EP3274440A4 (en) Detecting esophageal disorders
MA39753A (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
IL262852A (en) Treatment of complement-mediated disorders
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
FR3011467B1 (fr) Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
HUE037663T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP2870161A4 (en) OXABICYCLOHEPTANESE AND OXABICYCLOSES FOR THE TREATMENT OF REPERFUSION INJURIES
EP3370725A4 (en) PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP4223359C0 (en) Non-invasive device for treating gastro-esophageal reflux disease
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP2950762A4 (en) PREVENTIVE AND TREATING NEUROPATHY
EP2857037A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN BY ANTICROBIAL AGENTS
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders